NEUROL 0.25, 0.25 mg, tablets
Alprazolam
The active substance of Neurol is alprazolam. It belongs to a group of medicines called benzodiazepines (anxiolytic drugs).
Neurol is indicated for the treatment of symptoms of anxiety disorders in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This medicine is intended for short-term use only
Neurol should not be used in children and adolescents under 18 years of age.
Before starting treatment with Neurol, the patient should discuss it with their doctor:
Like other benzodiazepines, Neurol may cause anterograde amnesia, which occurs a few hours after taking the medicine. In such a case, the patient should have uninterrupted sleep for 7-8 hours.
Benzodiazepines and similar-acting substances should be used with caution in elderly patients, due to the risk of excessive sedation and (or) muscle weakness, which may lead to falls, often with serious consequences for such a patient.
Episodes of hypomania and mania have been reported in association with the use of Neurol in patients with depression.
Before planned surgery, the patient should inform their doctor about taking Neurol.
A decrease in the efficacy of the sedative effect of alprazolam (and other benzodiazepines) may occur with repeated use of the medicine for several weeks.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as those they plan to take.
The medicine should be taken before a meal or during a meal, with a small amount of liquid. Alcohol should not be consumed during treatment with Neurol.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor before using this medicine.
It is not recommended to use the medicine during pregnancy or when trying to conceive.
If the medicine is used during pregnancy or if the patient becomes pregnant while taking alprazolam, they should be examined for potential fetal risk. If it is necessary to administer the medicine in the last trimester of pregnancy, high doses should be avoided and the newborn should be monitored.
Benzodiazepines pass into breast milk in small amounts. This medicine should not be used during breastfeeding.
Neurol causes impairment of psychophysical abilities. Before taking Neurol, the patient should familiarize themselves with local traffic laws.
The patient should not drive vehicles or operate machinery while taking Neurol.
Neurol contains lactose monohydrate.
If the patient has been diagnosed with intolerance to some sugars, they should consult their doctor before taking the medicine.
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor or pharmacist.
Treatment should be as short as possible. The doctor should frequently assess the patient's condition and the need to continue treatment, especially if the severity of the symptoms decreases and may not require pharmacological treatment. The total treatment duration should not exceed 2-4 weeks. Prolonged treatment is not recommended.
When starting treatment, the doctor will inform the patient about the limited duration of therapy, the gradual reduction of the dose during withdrawal, and the possibility of withdrawal reactions.
During the use of benzodiazepines, including Neurol, dependence and emotional or physical dependence may develop. This risk may increase with the dose and duration of treatment, so the smallest effective dose should be used for the shortest possible time, and the need for continued treatment should be frequently assessed with the doctor.
Recommended dose
The dose is determined by the doctor based on the severity of symptoms and the patient's individual response to treatment. If severe adverse reactions occur after the initial dose, the doctor may decide to reduce the dose.
Symptomatic treatment of anxiety disorders
The recommended initial dose is 0.25 mg or 0.5 mg three times a day.
The doctor may decide to increase the dose depending on the patient's needs, up to a maximum daily dose of 4 mg, divided into smaller doses, taken throughout the day.
Neurol should not be used in children and adolescents under 18 years of age.
Use in patients with severe liver failure is contraindicated.
The recommended initial dose is 0.25 mg two or three times a day.
If necessary, the doctor may decide to gradually increase the dose depending on the patient's tolerance to the medicine. If adverse reactions occur, the doctor will decide to reduce the initial dose.
Taking a higher than recommended dose of Neurol may cause: ataxia (motor incoordination), drowsiness, speech disorders, coma, and respiratory depression. If worrying symptoms occur, the patient should immediately consult their doctor.
A double dose should not be taken to make up for a missed dose.
The patient should not stop taking the medicine on their own.
Since the treatment is symptomatic, after its discontinuation, the symptoms of the disease may return.
The doctor will decide to gradually reduce the dose.
In case of any further doubts about the use of this medicine, the patient should consult their doctor.
Like all medicines, Neurol can cause side effects, although not everybody gets them.
If any of the following side effects persist or are troublesome, the patient should inform their doctor. The occurrence of some side effects depends on the individual susceptibility of the patient and the dose of the medicine. Side effects are usually observed at the beginning of therapy. They disappear as treatment continues or when the dose is reduced.
The frequency of side effects observed in clinical trials and after the marketing of the medicine:
Additionally, especially in patients taking other psychotropic medicines, with mental disorders, or abusing alcohol, a paradoxical reaction may occur with symptoms such as anxiety.
Other side effects have been observed rarely or very rarely: motor disorders, epilepsy, psychotic symptoms, a feeling of changed self, agranulocytosis (significant decrease in granulocyte count), allergic reactions, or anaphylaxis (severe allergic reactions).
Benzodiazepines may cause physical and psychological dependence. If physical dependence occurs, sudden discontinuation of Neurol may cause withdrawal symptoms: headache, muscle pain, increased anxiety, feeling of tension, agitation, disorientation, irritability, changed perception of the environment or oneself, impaired hearing, stiffness, and paresthesia of the limbs, hypersensitivity to light, noise, and touch, hallucinations, and seizures, insomnia, and mood changes. These symptoms are usually more severe in patients treated for a long time, with high doses of benzodiazepines, and in case of sudden or rapid discontinuation of the medicine.
There have been reports of benzodiazepine abuse.
If any side effects occur, including those not listed in this leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C
02-222 Warsaw
Tel.: 22 49 21 301
Fax: 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
Store in a temperature below 25°C, in the original packaging.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Neurol 0.25: white or almost white tablets without a dividing line.
Neurol 1.0: white or almost white tablets with a dividing line; the tablet can be divided into equal doses.
Package size: 30 tablets.
Zentiva k.s., U kabelovny 130, Dolní Měcholupy, 102 37 Prague 10, Czech Republic
To obtain more detailed information about this medicine, the patient should contact the local representative of the marketing authorization holder in Poland:
Zentiva Polska Sp. z o.o.
Bonifraterska Street 17
00-203 Warsaw
Tel. +48 22 375 92 00
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.